Drug intelligence / Profile preview

hNPC01

Development stage: Phase 1
Lead developer: Hopstem Biotechnology
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Parenteral, Intralesional

Overview

hNPC01 is an investigational cell therapy composed of human forebrain neural progenitor cells (hNPCs) derived from human induced pluripotent stem cells (iPSCs). Developed by Hopstem Biotechnology, the therapy is designed to treat chronic ischemic stroke by promoting neural repair and functional recovery. It is administered via a single-dose intracerebral injection directly into the brain tissue. The progenitor cells are intended to differentiate into functional neurons and integrate into the peri-infarct environment, potentially restoring lost neural circuits and providing neurotrophic support to the damaged brain area.

Other names: human induced pluripotent stem cell-derived human forebrain neural progenitor cellsHopstem hNPC01

Beyond the preview

Go deeper on hNPC01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hNPC01.

Explore the full profile